- Home
- NTRA vs FTV Comparison
NTRA vs FTV Comparison
Compare NTRA & FTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- FTV
- Stock Information
- Founded
- NTRA 2003
- FTV 2015
- Country
- NTRA United States
- FTV United States
- Employees
- NTRA N/A
- FTV N/A
- Industry
- NTRA Medical Specialities
- FTV Industrial Machinery/Components
- Sector
- NTRA Health Care
- FTV Industrials
- Exchange
- NTRA Nasdaq
- FTV Nasdaq
- Market Cap
- NTRA 21.5B
- FTV 23.9B
- IPO Year
- NTRA 2015
- FTV N/A
- Fundamental
- Price
- NTRA $171.86
- FTV $69.63
- Analyst Decision
- NTRA Strong Buy
- FTV Buy
- Analyst Count
- NTRA 16
- FTV 14
- Target Price
- NTRA $185.56
- FTV $83.58
- AVG Volume (30 Days)
- NTRA 1.2M
- FTV 3.0M
- Earning Date
- NTRA 08-07-2025
- FTV 07-23-2025
- Dividend Yield
- NTRA N/A
- FTV 0.46%
- EPS Growth
- NTRA N/A
- FTV N/A
- EPS
- NTRA N/A
- FTV 2.28
- Revenue
- NTRA $1,831,000,000.00
- FTV $6,181,500,000.00
- Revenue This Year
- NTRA $19.92
- FTV N/A
- Revenue Next Year
- NTRA $16.02
- FTV $2.77
- P/E Ratio
- NTRA N/A
- FTV $30.67
- Revenue Growth
- NTRA 51.50
- FTV 0.85
- 52 Week Low
- NTRA $92.14
- FTV $60.39
- 52 Week High
- NTRA $183.00
- FTV $83.32
- Technical
- Relative Strength Index (RSI)
- NTRA 66.42
- FTV 44.59
- Support Level
- NTRA $161.39
- FTV $69.46
- Resistance Level
- NTRA $169.17
- FTV $71.26
- Average True Range (ATR)
- NTRA 4.86
- FTV 1.39
- MACD
- NTRA 0.57
- FTV -0.32
- Stochastic Oscillator
- NTRA 90.95
- FTV 20.31
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.